The article from Wamda titled “UAE-based biotech BioSapien secures $5.5 million pre-Series A” highlights the noteworthy advancements of BioSapien, a UAE-based healthtech company, particularly related to its innovative drug delivery solutions for cancer treatment. The recent funding round has positioned BioSapien for significant growth and development in this crucial sector.
BioSapien, founded in 2018 by Khatija Ali, focuses on developing cutting-edge drug delivery solutions specifically aimed at improving cancer treatment outcomes. BioSapien has successfully secured a $5.5 million pre-Series A funding round, led by Global Ventures, a prominent MENA-based venture capital firm, with additional backing from Dara Holdings.
The company’s flagship product, MediChip™, is a 3D-printed, slow-release drug delivery platform. MediChip™ adheres directly to tissues, minimising systemic side effects. This ensures a higher concentration of the drug within the tumor microenvironment, effectively reducing the required dosage while maintaining therapeutic efficacy.
The organization will use the recently acquired funding to launch clinical trials for MediChip™ in the UAE. It expects to begin enrolling patients in Abu Dhabi in the second quarter of 2025. The capital will further support advancements in product development, expansion of manufacturing capabilities, and talent acquisition.
The global cancer drug delivery market, valued at $247 billion, offers significant opportunities for companies like BioSapien. Notably, the global colorectal cancer market alone is valued at $19 billion, with both sectors experiencing considerable growth rates.
Khatija Ali, CEO and Founder of BioSapien, emphasises the high unmet need for effective drug release mechanisms with minimal side effects. She envisions MediChip™ improving the treatment journey for cancer patients by reducing adverse effects and potentially preventing life-altering surgeries.
BioSapien’s innovative technology is poised to disrupt the healthcare sector, particularly in cancer treatment. By providing on-the-go therapy aimed at local tumor treatment, BioSapien seeks to significantly enhance patient outcomes and improve quality of life during intensive treatments.
Overall, the article emphasises BioSapien‘s commitment to transforming drug delivery in cancer care, the substantial funding acquired, and its potential to create a meaningful impact on global cancer treatment solutions.
🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!
#SyenzaNews #globalhealth #healthcareInnovation
🌍 Can collaboration redefine Africa’s health landscape?
A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.
Look into the details of this transformative partnership and its implications for the future of healthcare in the region!
#SyenzaNews #globalhealth #HealthcareInnovation
🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?
A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.
Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.
#SyenzaNews #globalhealth #oncology #HealthTech
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
